Tesamorelin: What It Is and Who the Trials Studied

5 minute read

What Is Tesamorelin?

Tesamorelin is a man-made copy of a natural signal the body uses to tell the pituitary gland to release growth hormone.

The pituitary is a small gland at the base of the brain. One of its jobs is making growth hormone. It does not do this constantly; it releases it in bursts, when it gets the signal to. Tesamorelin is a copy of that signal.

The natural version breaks down in the blood within moments. Tesamorelin has a small chemical group added to one end, which shields it from the enzyme that would otherwise chop it up. The part the pituitary recognises is unchanged, so the gland responds to it in the same way.

Does It Contain Growth Hormone?

No. Tesamorelin contains no growth hormone at all, and this is the thing most often got wrong about it.

Tesamorelin is not growth hormone. It is the instruction to make growth hormone. The difference is real and it changes what the compound does:

• Give growth hormone directly and you replace the body’s own supply.
• Give tesamorelin and you prompt the body to release its own, in its normal on-off rhythm.

A compound that prompts a gland like this has a name: a secretagogue. It is worth knowing the word, because product listings often use it without explaining it.

Why Does It Clear the Body in Minutes?

Tesamorelin is gone from the bloodstream in about eight minutes. Descriptions of it as long-acting are simply wrong.

That sounds like a problem until you look at what it is doing. It only needs to reach the pituitary and set off a pulse. What happens next — the growth hormone released, and the slower changes that follow — carries on long after the tesamorelin itself has gone.

So judging it by how long it lasts is the wrong measure. It is a doorbell, not a houseguest.

Who Were the Trials Done On?

This is the single most important thing to understand about the evidence for tesamorelin, and it is usually left out.

Almost the entire published record comes from adults with HIV, on treatment, who had a build-up of fat around the abdomen. The trials were large and carefully run. The approved medical use is limited to exactly that group and no one else.

What those trials measured:

There is also almost no animal research on it, which is unusual. Most compounds in this catalogue have a large animal literature and little human data. Tesamorelin is the other way round.

What Have Regulators Said About It?

Two regulators reached opposite conclusions about tesamorelin, and both are worth knowing.

The United States approved it for one narrow use: reducing excess abdominal fat in adults with HIV-related fat redistribution. The approved labelling also states plainly that it is not for weight-loss management, and that long-term heart safety has not been established.

Europe did not approve it. The application was submitted and then withdrawn while under review. The published assessment said the reduction in abdominal fat had not been shown to produce an actual health benefit, raised concerns about long-term risk, and concluded the benefits did not outweigh the risks. Two follow-up safety studies meant to settle those questions were both stopped, so the questions are still open.

In Australia the TGA’s position is that unapproved peptide products have not been assessed for safety, quality or effectiveness. In vitro research requirements covers what that means for a purchaser.

How Is Tesamorelin Different From CJC-1295 Without DAC and Ipamorelin?

Tesamorelin, CJC-1295 without DAC and ipamorelin are three separate molecules. All three prompt the pituitary rather than supplying growth hormone, but two of them act at the GHRH receptor and the third acts at a different receptor altogether.

The naming trap sits on the middle row. Material sold as CJC-1295 comes in two forms whose published records are not interchangeable, and CJC-1295 with DAC and without works through how to tell which one a listing is describing.

What Do You Get When You Order It?

Australian Research Peptides supplies Tesamorelin as a freeze-dried powder in a sealed vial. Every batch is HPLC tested, and the certificate is published in the CoA library.

It is less stable once mixed than it is as a dry powder, so storage and handling matters more here than for most of the range.

Common Questions

Tesamorelin itself sits in the Australian Research Peptides catalogue as a single 10 mg vial under Growth Hormone Research, in stock and HPLC-tested with its certificate published, and goes out from Sydney to every Australian state and territory.

Read this article as plain text — Tesamorelin: What It Is and Who the Trials Studied, in Markdown — the full text in Markdown, without the page around it, for assistants, screen readers and offline reading.